• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS
  • Email newsletter

Pharma industry news

Bristol Myers Squibb logo

Phase 2 data for Opdivo (nivolumab) to be presented

Posted on: 30 October 2014 | Source: Bristol-Myers Squibb

Phase 2 objective response rate and survival data for Opdivo (nivolumab) in heavily pre-treated advanced squamous cell non-small cell lung cancer to be presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology...

Pills

Auditing is theme for next BGMA Quality Forum

Posted on: 30 October 2014 | Source: British Generic Manufacturers Association

Auditing will be a key theme of the British Generic Manufacturers Association’s (BGMA) next Quality Forum meeting on Wednesday, November 12th which is run in partnership with the MHRA...

Lilly shares technology insights on tuberculosis medicines

Lilly shares technology insights to increase supply of medicines for multidrug-resistant tuberculosis

Posted on: 30 October 2014 | Source: Eli Lilly and Company

Eli Lilly and Company published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB)...

Belen Garijo, CEO and president of Merck serono and Prof. Solomon Mpoke, Director and CEO of KEMRI

Merck Forms a Scientific Partnership with Kenya Medical Research Institute (KEMRI) as part of its Capacity Advancement Program in Africa

Posted on: 29 October 2014 | Source: Merck

Merck announced today the signature of a memorandum of understanding with Kenya Medical Research Institution (KEMRI) for a scientific partnership aimed at contributing to the country’s social and economic development. The partnership will cover research and development projects, programs and activities focused on malaria and schistosomiasis, as well as related co-infections...

Non Hodgkin's Lymphoma

Global Non-Hodgkin Lymphoma therapeutics market value to hit $9.2 billion by 2020

Posted on: 29 October 2014 | Source: GBI Research

The global Non-Hodgkin Lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 7.4%, says business intelligence provider GBI Research...

Eli Lilly logo

Lilly to participate in Credit Suisse 2014 Healthcare Conference

Posted on: 29 October 2014 | Source: Eli Lilly and Company

Eli Lilly and Company (LLY) will participate in the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, AZ, on Wednesday, November 12, 2014. Jeffrey Simmons, Senior Vice President and President, Elanco Animal Health, will make a formal presentation at 1:30 p.m. EST...

Christopher A. Viehbacher

Christopher A. Viehbacher removed as Sanofi’s Chief Executive Officer

Posted on: 29 October 2014 | Source: Sanofi

Sanofi's Board of Directors have decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi. As a consequence Christopher A. Viehbacher resigned as a director of Sanofi...

Eli Lilly logo

Lilly responds to decision in case of Terrence Allen, et al. v. Takeda

Posted on: 28 October 2014 | Source: Eli Lilly &Company

Eli Lilly and Company LLY, -2.58% issued the following statement in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 be reduced...

Boehringer Ingelheim logo

Boehringer Ingelheim introduces IDBS’ E-WorkBook Suite

Posted on: 28 October 2014 | Source: Boehringer Ingelheim

Global top 20 pharma company streamlines R&D IT with cross-domain platform...

Bristol Myers Squibb logo

Bristol-Myers Squibb enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy

Posted on: 28 October 2014 | Source: Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and F-star Alpha Ltd. announced that the companies, together with the F-star Alpha Ltd. shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102...

Ebola

SkyVision donates to The National Commission against Ebola in Guinea

Posted on: 28 October 2014 | Source: Distributed by APO (African Press Organization) on behalf of SkyVision Global Networks Ltd

The fund will be used to cover expenses and the needs of Ebola patients and affected families...

Moberg Pharma

First patient included in phase ll study of BUPI, a novel topical formulation for treatment of oral pain

Posted on: 28 October 2014 | Source: Moberg Pharma

Moberg Pharma AB announced that the first patient has been included in a randomized controlled phase ll study with BUPI, a novel topical formulation for the treatment of oral pain...